Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection

Sepsis is a life-threatening condition triggered by an extreme response of the body to an infection. It requires immediate medical intervention to prevent potential death or lasting damage. Delay in diagnosing patients with sepsis or septic shock is linked with heightened mortality and morbidity, emphasizing the critical need for prompt diagnosis to improve survival rates. Now, new research findings promise faster diagnosis and better outcomes for sepsis and septic shock patients.

In the study led by Murdoch University (Perth, Australia), researchers successfully used blood plasma metabolic phenotyping to accurately diagnose sepsis or septic shock within an hour of collecting blood samples. This method marks a significant improvement over traditional pathogen culturing techniques, which may take days to yield results. According to the researchers, metabolic signatures were the key to the breakthrough. The study involved the analysis of blood plasma samples collected from 152 patients admitted to the Intensive Care Unit (ICU) within 48 hours—comprising 62 without sepsis, 71 with sepsis, and 19 with septic shock.

The metabolic profiling revealed that patients with sepsis or septic shock displayed higher levels of neopterin and lower levels of HDL cholesterol and phospholipid particles compared to those without sepsis. Septic shock patients could be differentiated from those with only sepsis through different concentrations of 10 specific lipids, including notably reduced levels of five phosphatidylcholine species, three cholesterol esters, one dihydroceramide, and one phosphatidylethanolamine. Utilizing these 15 parameters, which include various metabolites, lipids, lipoproteins, and inflammatory markers, the study achieved high accuracy in accurately classifying patients into their respective clinical outcomes. The research underscores the potential of plasma metabolic phenotyping within 48 hours of ICU admission as a dependable tool for diagnosing sepsis and differentiating between sepsis and septic shock based on lipid profiles.

“As well as impacting individuals and families, sepsis and septic shock pose a significant economic burden to our society,” said Dr. Sam Lodge, from Murdoch University’s Australian National Phenome Centre. “While further validation with a larger cohort is required, this study provides a proof of concept for the potential use of metabolic phenotypes in better diagnosing these conditions.”

Related Links:
Murdoch University

Visit expo >

Gold Member

Pharmacogenetics Panel

VeriDose Core Panel v2.0

Verification Panels for Assay Development & QC
Seroconversion Panels

New

Silver Member

Verification Panels for Assay Development & QC

Seroconversion Panels

New

TORCH Infections Test

TORCH Panel